Результаты поиска

Treatment of psychotic and behavioral symptoms with clozapine, aripiprazole, and reboxetine in a patient with Huntington's disease.

We report on the successful use of a combined psychopharmacological treatment in a patient with Huntington's disease, at age 39, suffering from severe psychotic and behavioral symptoms. He presented with a schizophreniform psychosis accompanied by aggressive behavior leading to admission to the locked ward of our hospital. After unsatisfactory control of the psychiatric symptoms with olanzapine, risperidone, and amisulpride, we introduced aripiprazole. This did not affect the psychotic symptoms; however, led to an improvement in aggressive behavior, motivation, and even chorea. Accordingly, we…

The cognitive profile of aripiprazole differs from that of other atypical antipsychotics in schizophrenia patients.

We investigated the effects of the atypical antipsychotics risperidone, olanzapine, and aripiprazole on the cognitive functions of Japanese patients with schizophrenia with respect to dosage amounts and dosing schedules. We performed a cross-sectional survey using the Brief Assessment of Cognition in Schizophrenia - Japanese Language Version (BACS-J) to evaluate the neurocognitive functions of 101 schizophrenic patients who took the same dose of one of the three aforementioned antipsychotics for at least 3 months. The BACS-J composite score correlated negatively with the prescribed dosages of …

Switching to aripiprazole in subjects with pervasive developmental disorders showing tolerability issues with risperidone.

BACKGROUND: Subjects with Pervasive Developmental Disorders (PDD) often exhibit behavioral symptoms such as aggressiveness and irritability, which are targets of psychopharmacologic intervention. This retrospective study was designed to examine children and adolescents with PDD experiencing tolerability issues with risperidone treatment, and thereby assess the efficacy and tolerability of switching to aripiprazole. METHODS: This naturalistic study included 23 subjects with PDD (16 males, 7 females, age range 9-24 years, mean age 15.1±3.9 years) diagnosed according to DSM-IV criteria and follo…

Use of aripiprazole in adolescents with a history of lupus-associated psychosis and refractory psychiatric manifestations.

Neurologic and psychiatric manifestations are prevalent in children and adults with lupus (labeled by convention neuropsychiatric systemic lupus erythematosus or NPSLE). However, there is a paucity of data on the evaluation and management of NPSLE in youth, with only a few publications describing the use of atypical antipsychotics in children and adolescents with lupus. In children, aripiprazole, a D2/5-HT1A partial agonist, appears to cause less prominent metabolic derangements than other second-generation antipsychotics. This agent may be an important tool in the treatment of pediatric patie…

Effects of amisulpride and aripiprazole on progressive-ratio schedule performance: comparison with clozapine and haloperidol.

Clozapine and some other atypical antipsychotics (e.g. quetiapine, olanzapine) have been found to exert a characteristic profile of action on operant behaviour maintained by progressive-ratio schedules, as revealed by Killeen's Mathematical Principles of Reinforcement model of schedule-controlled behaviour. These drugs increase the value of a parameter that expresses the 'incentive value' of the reinforcer (a) and a parameter that is inversely related to the organism's 'motor capacity' (δ). This experiment examined the effects of two further atypical antipsychotics, aripiprazole and amisulprid…

Who responds to aripiprazole in clinical practice? An observational study of combination versus monotherapy.

We aimed to study aripiprazole, as monotherapy and combined with other antipsychotics, in routine clinical practice, to identify patients who had a favourable clinical response. We retrospectively identified all secondary care psychiatric patient records started on aripiprazole (n = 85). We assigned Clinical Global Impression scores to measure effectiveness. We examined demographic and clinical correlates of patients who improved (CGI Improvement scores < 5) versus those who did not improve (CGI > or = 5). 56 patients (66%) received aripiprazole as monotherapy, 29 patients (34%) in combination…

Suppression of dopamine-related side effects of morphine by aripiprazole, a dopamine system stabilizer.

Dopamine receptor antagonists are commonly used to counter the adverse effects of opioids such as hallucinations, delusions and emesis. However, most of these agents themselves have side effects, including extrapyramidal symptoms. Here, we investigated the effect of the dopamine system stabilizer aripiprazole on morphine-induced dopamine-related actions in mice. Morphine-induced hyperlocomotion and reward were significantly suppressed by either the dopamine receptor antagonist prochlorperazine or aripiprazole. Catalepsy was observed with a high dose of prochlorperazine, but not with an even hi…

A case report of neuroleptic malignant syndrome without fever in a patient given aripiprazole.

Neuroleptic malignant syndrome (NMS) is a rare disorder seen most often in patients exposed to antipsychotic medications. This syndrome is g … The authors present an unusual case of NMS in a schizophrenic patient without fever who had been on aripiprazole. To date, there are only three possible reported cases of NMS related to aripiprazole. This case report serves to remind clinicians of the essential features in the diagnosis and management of NMS.

Aripiprazole as an augmentor of selective serotonin reuptake inhibitors in depression and anxiety disorder patients.

More than half of anxiety and depression patients treated with an adequate course of antidepressants fail to fully improve. We retrospectively examined whether treatment-resistant depression and anxiety disorder patients responded to and tolerated augmentation with the atypical antipsychotic, aripiprazole. We report on patients with depression and anxiety disorders, including panic disorder, generalized anxiety disorder, social anxiety and post-traumatic stress disorder, who had an incomplete response to a variety of selective serotonin reuptake inhibitors (SSRIs) and who received augmentation…

Aripiprazole attenuates the discriminative-stimulus and subject-rated effects of D-amphetamine in humans.

The results of animal research suggest that the use of partial agonists at dopamine (DA) D2 receptors may be an effective strategy for the treatment of stimulant dependence. Aripiprazole is an atypical antipsychotic that has partial agonist activity at D2 receptors. In this experiment, seven human participants with a history of nontherapeutic stimulant use learned to discriminate 15 mg oral D-amphetamine. After acquiring the discrimination (ie > or =80% correct responding on four consecutive sessions), the effects of a range of doses of D-amphetamine (0, 2.5, 5, 10, and 15 mg), alone and in co…

Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials.

Aripiprazole is a novel antipsychotic with a unique mechanism of action. Presented here is a pooled analysis of safety and tolerability data from all completed short-term, placebo-controlled trials in schizophrenia from the aripiprazole clinical development program. Data were analyzed from five 4- to 6-week double-blind multicenter studies of patients hospitalized with acute relapse of schizophrenia or schizoaffective disorder randomized to aripiprazole (n=932), placebo (n=416), or haloperidol (n=201). Daily aripiprazole doses ranged from 2 to 30 mg. Safety assessments included adverse event (…

Aripiprazole and CYP2D6: A retrospective cohort study evaluating the impact of phenotype on metabolic abnormalities.

PURPOSE: The aim of this study was to investigate the influence of CYP2D6 functionality on metabolic abnormalities in patients prescribed aripiprazole. METHODS: A retrospective cohort review was conducted in patients who had CYP2D6 genotyping and an oral prescription for aripiprazole. Primary outcomes were changes in metabolic parameters from baseline based on CYP2D6 genotype-based phenotype. Patients concurrently taking medications that cause CYP2D6 inhibition were classified as phenoconverters and were categorized as poor metabolizers in subanalyses. Index and post-aripiprazole (after eithe…

In Vitro/In vivo evaluation of aripiprazole long-acting injectable microsuspension and development of IVIVC.

Aripiprazole microcrystalline suspensions with varying particle sizes were prepared by wet media milling and characterized and compared with a Reference listed drug (RLD); The particle-size related properties were assessed by zeta potential, laser diffraction, and dynamic particle imaging, while morphology and solid-state properties were characterized by scanning electron microscopy (SEM), powder X-ray diffraction (XRD), thermogravimetric analysis (TGA), differential scanning calorimetry (DSC), and Raman spectroscopy to provide a robust quality control. Because the paddle method from the FDA d…

Functional Brain Network Abnormalities and Aripiprazole's Modulatory Effects in Pediatric Tic Disorder.

BACKGROUND: This study aimed to investigate functional brain network characteristics in pediatric tic disorder (TD) patients and explore the effects of aripiprazole treatment on the functional brain network. METHODS: Resting-state electroencephalogram (EEG) was recorded from 40 TD patients and 30 matched healthy controls to compare functional brain network differences between TD patients and healthy individuals. Additionally, 26 of these TD patients underwent a 12-week aripiprazole treatment and were evaluated for changes in their functional brain networks before and after treatment. Function…

A giant fecaloma causing stercoral colitis secondary to aripiprazole and benztropine: A case report.

BACKGROUND: Fecaloma is a mass of hardened feces impacted in the rectum and sigmoid. When the colonic mucosal wall and vasculature are compressed, stercoral colitis, a rare type of inflammatory colitis, may occur. Despite being connected to psychiatric patients and antipsychotic medications in the literature, fecaloma remains a significant, yet often overlooked, cause of morbidity and mortality in this population. CASE PRESENTATION: A 43-year-old patient with schizophrenia being treated with aripiprazole and benztropine lost follow-up and eventually presented to the emergency department with …

Сравнение эффекта диалектической терапии поведения и арипипразола на эмоциональную разводню в пациентах с гиперсексуальностью.

Фон. Сексуальные желания являются одной из естественных потребностей каждого человека, и если они не используются в правильном направлении, они могут привести к проблемам и различным сексуальным расстройствам, включая гиперсексуальность. Целью этого исследования было сравнить эффекты диалектической поведенческой терапии (ДПТ) и арипипразола на эмоциональную разводку у пациентов с гиперсексуальностью. Материалы и методы. Это исследование было квазиэкспериментальным, с двумя экспериментальными группами, контрольной группой, предварительным тестом, посттестом и фазой последующего наблюдения. Для

Совпадение в аннотации оригинала
BackgroundSexual desires are one of the natural needs of each person being, which, if not used in the right direction, may become problematic and lead to various sexual disorders, including hypersexuality. This study aimed to compare the effects of dialectical behavior therapy (DBT) and aripiprazole on emotional divorce in hypersexual patients.Materials and …

Influence of CYP2D6 phenotype on adherence, adverse effects, and attitudes in aripiprazole and risperidone users.

Non-adherence and negative attitudes towards medication are major problems in treating psychotic disorders. Cytochrome P450 2D6 (CYP2D6) contributes to the metabolism of aripiprazole and risperidone, and variations in CYP2D6 activity may affect treatment response or adverse effects. However, the impact of these variations on adherence and medication attitudes is unclear. This study investigates the relationships between CYP2D6 phenotype, self-reported adherence, adverse effects, and attitudes among aripiprazole and risperidone users. The study analysed data from the SUPER-Finland cohort of 10,…